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New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly
effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular safety. The most
common side effect of VEGF signaling pathway (VSP) inhibition is the development of systemic hypertension. We
review the incidence, possible mechanisms, significance and management of hypertension in patients treated with
VSP inhibitors.
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The importance of adequate diagnosis and management
of hypertension in patients with underlying malignancy
is well-known [1]. Poorly controlled hypertension influ-
ences cancer management, leading to temporary or
complete cessation of life-saving therapies. Depending
on the type and dose of treatment, systemic hyperten-
sion of new-onset is a common side effect of many anti-
cancer agents, particularly the vascular endothelial
growth factor (VEGF) signaling pathway (VSP) inhibi-
tors. In this review article we discuss the evidence, pro-
posed mechanisms and management of systemic
hypertension secondary to VSP inhibition.Pathogenesis of hypertension secondary to VSP inhibition
Cancer cell growth and proliferation mostly depends on a
blood supply, which is provided through angiogenesis [2].
Angiogenesis is controlled by many growth factors
through their specific receptor tyrosine kinases and activa-
tion of multiple tyrosine kinase pathways. VEGF and its
receptors (VEGFR) are one of the most important growth
factor pathways and play major role in endothelial cell
function [3]. VEGF inhibition has significantly advanced
the treatment of cancers leading to prolonged survival in* Correspondence: zaza@013.net
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targeted at various levels in the signaling cascade, includ-
ing the VEGF molecule (by monoclonal antibodies, eg,
bevacizumab), its receptors (recombinant soluble VEGF
receptor trap, Ziv-Aflibercept) or downstream signaling
pathways (small molecule receptor and non-receptor tyro-
sine kinase inhibitors, e.g. sunitinib, sorafenib). While it
was thought that adverse effects of anti-angiogenesis ther-
apy would be minimal it has become evident that systemic
hypertension is the commonest and most significant car-
diovascular side effect [4].
VEGF binds three tyrosine kinase receptors (VEGFR-1
[Flt-1], VEGFR-2 [Flk-1/KDR], and VEGFR-3 [Flt-4]) [5].
VEGFR-1 and VEGFR-2 are expressed predominantly in
endothelial cells, with VEGF-A binding to VEGFR-2 hav-
ing the major biological effects [6]. Binding of VEGF to
VEGFR-2 initiates a tyrosine kinase-signaling cascade
that stimulates production of factors that induce vaso-
dilation, cell proliferation/survival, migration, and differ-
entiation into mature blood vessels.
The pathophysiological mechanisms that result in the
development of hypertension during therapy with VSP
inhibitors is unclear.
There are several proposed mechanisms for VSP
inhibitor-associated hypertension: reduction in nitric
oxide (NO) production, increased expression of pro-
hypertensive agents such as endothelin-1 (ET-1), micro-
vascular rarefaction, activation of renin-angiotensinarticle is distributed under the terms of the Creative Commons Attribution 4.0
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mechanical properties of large vessels (arterial stiffness).
VEGF induces the release of NO and prostacyclin
(PGI2) by endothelial cells [7]. Blocking VSP will there-
fore decrease the secretion of these vasodilators and ele-
vate systemic vascular resistance with a subsequent
increase in blood pressure [8]. Experimental data that
antiangiogenic drugs decrease NO bioavailability is
contradictory. VEGF inhibition in humans is associated
with decreased serum levels of NO metabolites [9] while
no difference in flow-mediated dilation, a surrogate for
NO bioavailability, is observed.
An alternative mechanism is that hypertension results
from increased levels of the potent vasoconstrictor ET-1.
Sunitinib-induced hypertension is partially abolished by
ETA and ETB receptor antagonist macitentan. An in-
crease in ET-1 with concomitant renal toxicity, second-
ary to VSP inhibition is referred to as “preeclampsia”
[10] because both syndromes may have the same clinical
features of hypertension, proteinuria and glomerular
endotheliosis.
VEGF provides a survival signal to endothelial cells
and in cancer xenograft models, endothelial cell loss
within tumors is observed within days after initiation of
antiangiogenic therapy. VEGF promotes endothelial cell
survival and, conversely, inhibition of VEGF leads to
endothelial cell apoptosis and chronic remodeling of the
capillary beds, a process referred to as capillary rarefac-
tion. Consequently, rarefaction, the presence of a dimin-
ished number of microvessels, has frequently been
proposed as a mechanism of VSP inhibitor-associated
hypertension [11]. Human studies demonstrate a signifi-
cant decrease in dermal capillary density and decreased
capillary dilatory response after VSP inhibitor treatment,
implicating functional as well as anatomic attenuation of
vessel density [12]. The role of rarefaction in the devel-
opment or maintenance of hypertension remains ques-
tionable [13].
Activation of the renin-angiotensin-aldosterone
(RAAS) pathway secondary to VSP inhibition is plausible
biologically. Endothelial dysfunction caused by VSP in-
hibition might be expected to cause glomerular ischemia
and upregulation of RAAS but in fact experimental evi-
dence is not supportive of significant role of RAAS in
mediating blood pressure elevation with VEGF inhib-
ition. Renin and aldosterone levels did not increase after
treatment with sorafenib [14]. Renin messenger RNA
and aldosterone urinary excretion were actually de-
creased in DC101 (VEGF inhibitor) treated mice when
compared with controls [8]. This view is challenged by
the experimental evidence from mice treated with an
anti-murine VEGF-A monoclonal antibody for 5 weeks
[15]. In this study the inhibition of angiotensin-
converting enzyme (ACE) by ramipril almost entirelyprevented the adverse hemodynamic effects and LV re-
modeling in anti-VEGF–treated mice.
The renal effects of VEGF inhibition such as throm-
botic microangiopathy or renovascular dysregulation
may also contribute to hypertension [16].
Oxidative stress (increased bioavailability of reactive
oxygen species) might also contribute to the develop-
ment of hypertension during antiangiogenic therapy via
oxidation of NO, thereby decreasing NO-mediated vaso-
dilator tone [17].
Alterations in pressure-natriuresis relationship caused
by VSP inhibition may explain the development of
hypertension. Decreased levels of NO cause sodium re-
tention and extracellular volume increase resulting in
perpetuation of hypertension by changing the set-point
for sodium excretion [18].
Recent observational study elegantly demonstrates that
large artery properties are affected by VSP inhibition by
sunitinib or sorafenib. These drugs cause the increase in
arterial stiffness and this increase is partially independ-
ent of the blood pressure change [19].
Despite the lack of a comprehensive model, new-onset
hypertension seems to be an on-target, intended effect
of VEGF-pathway blockade during treatment with VSP
inhibitors. On-target refers to exaggerated and adverse
pharmacologic effects of VSP inhibitors at the target of
interest (i.e. VEGF pathway). This concept is further
supported by evidence that bevacizumab, a monoclonal
anti-VEGF-A antibody, and aflibercept, a soluble recep-
tor with affinity to VEGF-A and -B, are also strong in-
ducers of hypertension [20, 21]. Inhibition of the VEGF
pathway induces hypertension as a class effect; VEGFR-2
is most prominent of those [22–24].
In the majority of cases, proteinuria and hypertension
resolve or significantly improve with removal of anti-
VEGF therapy. There have been reports, however, of
resolution of nephrotic range proteinuria after cessation
of treatment, but with limited recovery of actual renal
function [25].
Incidence and timing of new –onset hypertension
New-onset hypertension may occur in cancer patients,
regardless of treatment type or even in those not receiv-
ing treatment. The reported incidence depends on many
factors including the different classification systems used
by oncology and cardiac societies. In 2010 the National
Cancer Institute updated Common Terminology Criteria
for Adverse Events (CTCAE version 4.03) [26] in order
to reflect more closely the Seventh Report of the Joint
National Committee of Prevention, Detection, Evalu-
ation, and Treatment of High Blood Pressure (JNC7)
guidelines for hypertension. Specifically, the definition of
hypertension and goals of treatment vary among differ-
ent professional societies [27–30]. It should be noted
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remained relatively static, the numeric values used to
further classify hypertension severity has changed over
this timespan, as described in Table 1.
There is a great variability between the different VSP
inhibitors in terms of the number of trials published, the
variety of study populations and their sizes. Many publi-
cations include only reports of common (>10 % of cases)
adverse events potentially underestimating the true inci-
dence of hypertension [31, 32].
Most of treatment-induced hypertension are reported
to be low-grade, and manageable with antihypertensive
medications. Reports of hypertension requiring treat-
ment cessation are scarce. The reported incidence of all-
grade hypertension ranges from 28 % in the initial beva-
cizumab trials [33] with similar frequency for sorafenib
[34], sunitinib [35], and vandetanib [36] and reaching
about 40 % with pazopanib [37] and axitinib [38]. Hyper-
tension incidence is higher with more potent VSP inhibi-
tor therapies probably representing on-target effect. Of
all VSP inhibitors axitinib, regorafenib and lenvatinib
have the highest reported rates of all-grade and high-
grade (grade ≥ 3) treatment-induced hypertension
(Table 2).
Incidence of hypertension depends on drug variables
(type of drug, dose and schedule used) and patients’
characteristics [39]. An absolute blood pressure increase
occurs in the majority of patients, with rapid onset after
the first administration of the drug. In the real-world
registry of Partners Healthcare [40] the absolute ob-
served mean increase has been described at 21 mmHg
for systolic and 15 mmHg for diastolic blood pressure
[40]. Risk factors included pre-existing hypertension
(65.4 %), age > 60 years and body mass index (BMI) ≥25.





Grade 1 Asymptomatic Transient (<24 h) Increase >20
(diastolic) > 150/100 if previously normal
Grade 2 Recurrent/persistent (≥24 h) symptomatic increase >20
(diastolic) > 150/100 if previously normal
Grade 3 Requiring >1 drug Requiring more intensive therapy
than previously
Grade 4 Life-threatening consequences
Grade 5 ND
Abbreviations: CTCAE common terminology criteria for adverse events, JNC joint nat
of cardiology, ND not defined
a All numeric blood pressure values are in mm Hg
b The current JNC-8 report (2013) [115] does not classify grades of hypertensionprior use of specific anti-hypertensive medications were
not significant risk factors [40].
Specific agents associated with the development of
hypertension
Bevacizumab
Bevacizumab (Avastin®, Genentech/Roche) is a monoclo-
nal antibody (mAb) that targets the VEGF pathway [41].
Most clinical trials compare combination therapy with
bevacizumab and standard chemotherapy versus stand-
ard chemotherapy alone.
The incidence rate of all-grade and high-grade hyper-
tension associated with bevacizumab is 23.6 % (RR 3.02,
95 % CI 2.24–4.07, p < 0.001) and 7.9 % (RR 5.28, 95 % CI
4.15–6.71, p < 0.001), respectively [42]. The malignant
mesothelioma trial reported the highest incidence of high-
grade hypertension (22.0 %), and the lowest rates were
documented in pancreatic cancer (5.5 %). Unlike disease-
specific effects seen in small-molecule TKIs that are VSP
inhibitors, patients suffering from RCC had a 7.1 % inci-
dence rate of high-grade hypertension, which was slightly
lower than the overall rate of 7.9 % seen in patients with
other malignancies [42]. While high-dose bevacizumab
clearly seems to be linked with treatment-induced hyper-
tension, the significance for low-dose regimens remains
unsettled [42, 43]. Treatment-induced hypertension has
not been shown to be a class effect in other mAbs that tar-
get the VEGF signaling pathway [44].
Sunitinib
Sunitinib malate (Sutent®, SU11248, Pfizer) is multi-
targeted tyrosine kinase inhibitor (TKI) with inhibitory
effects on multiple tyrosine kinase receptors, including
VEGFR 1, 2, and 3, platelet-derived growth factor recep-
tors (PDGFR) a and b, FMS (Feline McDonoughCTCAE 4.03 (2010)(26) JNC-7 (2003)(28)b ESH/ESC
(2013)(27)
Systolic Diastolic Systolic Diastolic Systolic Diastolic
120–139 80–89 140–159 90–99 140–159 90–99
140–159 90–99 ≥160 ≥100 160–179 100–109
≥160 ≥100 ND ND ≥180 ≥110
Life-threatening
consequences
ND ND ND ND ND
Death ND ND ND ND ND
ional committee, ESH European society of hypertension, ESC European society
Table 2 Relative risk of all-grade and high-grade (grade≥ 3) hypertension of several VSP inhibitor agents, described in meta-
analyses
All grade hypertension High grade hypertension
RRa 95 % CI p Value RRa 95 % CI p Value
Bevacizumab [33] 3.02 2.24–4.07 <0.001 5.28 4.15–6.71 0.001
Sunitinib [52] 3.44 0.62–19.15 0.16 22.72 4.48–115.29 <0.001
Axitinib [38] 3.00 1.29–6.97 0.01 1.71 1.21–2.43 0.003
Sorafenib [62] 3.07 2.05–4.60 <0.01 3.31 2.21–4.95 <0.01
Pazopanib [65] 4.97 3.38–7.30 <0.001 2.87 1.16–7.11 0.023
Lenvatinib [69] 7.44 4.31–12.85 <0.001 18.2 5.90–56.32 <0.001
Vandetanib [36] 5.10 3.76–6.92 <0.001 8.06 3.41–19.04 0.001
Regorafenib [74] 3.76 2.35–5.99 <0.001 8.39 3.10–22.71 0.001
Abbreviations: RR relative risk, CI confidence interval
a Relative risk of new onset hypertension during trial period in interventional group compared to control
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receptor tyrosine kinase [45–49]. Treatment induced
hypertension has been associated with sunitinib therapy
for different forms of cancer. In the meta-analysis of
early clinical trials including 4999 patients receiving su-
nitinib, the incidence of all-grade and high-grade hyper-
tensions were 21.6 % (95 % CI: 18.7–24.8 %) and 6.8 %
(95 % CI: 5.3–8.8 %) respectively. The risk may vary with
tumor type and the dosing schedule of sunitinib. Suniti-
nib was associated with a significantly increased risk of
high-grade hypertension (RR = 22.72, 95 % CI: 4.48 to
115.29, p < 0.001) and renal dysfunction (RR: 1.36, 95 %
CI: 1.20 to 1.54, p < 0.001) in comparison with controls.
Further subgroup analysis revealed a significant risk of
hypertension for patients with RCC (25.9 % versus
20.4 %, RR 1.27, 95 % CI: 1.13–1.43 %, p < 0.001). One
possible explanation is that patients with RCC may have
higher VEGF level than non-RCC patients, and the
resulting overall anti-VEGF effect of sunitinib may be
more evident. Alternatively, patients with RCC may have
reduced renal function due to prior nephrectomies, and
thus may have reduced excretion of sunitinib level lead-
ing to increased sunitinib exposure or directly contribute
to the development of hypertension. Indeed, majority of
patients with RCC in these trials had nephrectomies be-
fore receiving sunitinib [35].
More recent phase II trials have shown a significant
risk of treatment-induced hypertension with sunitinib in
patients suffering from pancreatic neuroendocrine tu-
mors [50] and endometrial carcinoma [51]. Treatment-
related hypertension incidence varied with the dose of
sunitinib in a phase II study of women with epithelial
endometrial and primary peritoneal cancers [52, 53].
Axitinib
Axitinib (Inlyta®, AG-013736, Pfizer) is a selective
tyrosine-kinase inhibitor of VEGFR 1, 2, and 3 [54]. Ameta-analysis of two phase III and eight phase II trials
including 1148 patients showed high incidence rates for
all-grade and high-grade hypertension, 40.1 and 13.1 %
respectively. Compared with placebo, treatment with
axitinib was associated with a significant risk for all-
grade (RR 3.00, 95 % CI 1.29 to 6.97, p = 0.011) and
high-grade hypertension (RR 1.71, 95 % CI 1.21 to 2.43,
p = 0.003) [38]. Similar to the trend discussed regarding
subgroup differences between treatment-induced hyper-
tension in RCC and non-RCC patients, axitinib treat-
ment had a significantly higher risk for all-grade
hypertension (RR 1.69, 95 % CI 1.45 to 1.97, p < 0.001)
and high-grade hypertension (RR 3.20, 95 % CI 2.30 to
4.46, p < 0.001) [38]. We further analyzed the data in the
three non-RCC trials, and found that, in contrast to su-
nitinib, the risk of all-grade (RR 3.98, 95 % CI 2.68 to
5.89, p < 0.001) and high-grade hypertension was signifi-
cant (RR 4.75, 95 % CI 1.86 to 12.18, p < 0.001) [55–57].
An additional meta-analysis that focused on patients
with pancreatic malignancies also yielded similar re-
sults [58].
Rini et al. have published their results of 53 patients
after 5-year follow-up and showed an even higher inci-
dence rate of all-grade hypertension of 63.5 %. The inci-
dence rate of high-grade hypertension incidence was
13.5 %, similar to that shown in short-term studies [59].
The incidence rates of treatment-induced hyperten-
sion associated with axitinib, are higher than those
described for all multi-targeted TKIs discussed in this
review. This contrasts with the evidence that multi-
targeted agents are more prone to this effect. We
challenge this principal, further suggesting alternative
explanations for these observations: 1) axitinib might
have more undiscovered targets of action; 2) the se-
lective nature of axitinib encouraged the use of higher
dosages, thus increasing efficacy and associated tox-
icity of the anti-VEGFR effect.
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Sorafenib (Nexavar®, BAY 43–9006, Bayer) is a multi-
targeted TKI, which effects Raf kinase, VEGFR 1, 2, and
3, PDGFR-b, FLT-3, c-KIT and RET-receptor tyrosine
kinase [60]. Treatment-induced hypertension with soraf-
enib is documented in different forms of cancer.
In three meta-analysis studies of sorafenib-associated
hypertension, the incidence rates of all-grade and
high-grade hypertension were 19.1–23.4 and 4.3–
6.0 % [61, 62] respectively. The three studies showed
similar relative risks; in the largest metaanalysis of 14
randomized controlled trials and 39 prospective
single-arm trials involving 13,555 patients the relative
risks of all-grade and high-grade hypertension were
3.07 (95 % CI 2.05 to 4.60, p < 0.01) and 3.31 (95 %
CI 2.21 to 4.95, p < 0.01), respectively [61]. A sub-
group analysis showed patterns similar to those de-
scribed for other VEGFR inhibitors, with a
significantly higher risk in patients suffering from
RCC. In contrast to sunitinib, the incidence of treat-
ment–associated hypertension with sorafenib was in-
creased in patients with non-RCC, hepatocellular
carcinoma (HCC), and non-small cell lung cancer
(NSCLC). There was no associated risk of hyperten-
sion for patients with pancreatic cancer, breast cancer
or acute myeloid leukemia. In patients with melan-
oma, only the risk of developing high-grade hyperten-
sion was significant [61].
Concomitant treatment with sorafenib and chemother-
apy attenuated treatment-induced hypertension, without
the need to lower the dose of sorafenib [61, 62].
Pazopanib
Pazopanib (Votrient®, GW786034, Novartis), is a multi-
targeted TKI, targeting VEGFR 1, 2, and 3, PDGFR-a
and PDGFR-b, and c-kit [63, 64]. A large meta-analysis
found the incidence of all-grade and high-grade
treatment-induced hypertension of 35.9 and 6.5 %, re-
spectively. RCC patients had the highest incidence rates,
however non-RCC patients also had a significant risk of
developing hypertension [37].
In RCC patients pazopanib is associated with a higher
risk of all-grade treatment-induced hypertension com-
pared to sorafenib (RR 1.99, 95 % CI 1.73 to 2.29, p =
0.001) and sunitinib (RR 2.20, 95 % CI 1.92 to 2.52, p =
0.001). There was no significant difference regarding the
incidence of high-grade hypertension between these
three agents [37].
Although TKIs targeting the VEGFR pathway are more
prone to causing hypertension in RCC patients, pazopa-
nib has the highest documented rate of treatment-
induced hypertension in patients with thyroid carcin-
oma, with all-grade hypertension occurring in 54.1 % of
cases [65], versus 38.2 % in RCC patients [66, 67]. Wehave found that patients with metastatic thyroid carcin-
oma have a significant risk of developing hypertension,
even when compared with RCC patients (RR 1.95, 95 %
CI 1.42 to 2.69, p < 0.0001). This is in contrast to the
trend of higher rates of treatment-induced hypertension
seen with other VSP inhibitors discussed in this review.
Lenvatinib
(Lenvima®, E7080, Eisai) is an oral, multi-targeted tyro-
sine kinase inhibitor of the VEGFRs 1, 2, and 3, fibro-
blast growth factor receptor (FGFR) 1 through 4,
PDGFR α, RET, and KIT signaling networks [68]. The
drug was recently approved by the U.S. Food and Drug
Administration [69] for the treatment of Iodine-131-
refractory thyroid cancer [69]. Any grade hypertension
was observed in 69.3 % of the patients in the lenvatinib
group compared to 42.9 % in the placebo group and
hypertension grade ≥3 was found in 9.2 and 2.3 % of the
levatinib and placebo groups, respectively. Despite the
high rate of new-onset hypertension, discontinuation of
the drug was necessary in 1.1 % of patients only and
dose reduction/interruption occurred in 19.9 % of the
drug group.
Vandetanib
Vandetanib (Caprelsa®, ZD6474, Astra-Zeneca) targets
VEGFR 2, VEGFR 3, and RET tyrosine kinase receptors.
It has a negligible and week effect on VEGFR 1 [70].
This drug is not indicated for RCC as most of other
agents previously reviewed. A meta-analysis including
1414 cases from 11 trials found all-grade and high-grade
treatment-induced hypertension in an overall cancer
population of 24.2 and 6.4 %, respectively. Both all-grade
and high-grade hypertension rates were higher in medul-
lary thyroid cancer (MTC) patients - 32.1 and 8.8 %, re-
spectively. NSCLC patients also had a slightly higher
incidence then the other patient groups (21.8 and 7.6 %
versus 15.4 and 3.4 %, respectively). Overall there was a
significant risk of treatment-induced hypertension,
which according to a subgroup analysis varied between
the MTC, NSCLC and non-MTC/NSCLC groups in line
with the corresponding incidence rates [36].
Regorafenib
Regorafenib (Stivarga®, BAY 73–4506, Bayer) is a multi-
targeted TKI that broadly targets VEGFR 1, 2, and 3,
TIE-2, Ret-receptor, PDGF-b, basic fibroblast growth
factor receptor-1, c-KIT, RAF-1, BRAF and p38 MAP
kinase [71, 72]. A meta-analysis of 750 patients from five
trials found a pooled incidence rate of all-grade and
high-grade hypertension of 44.4 and 12.5 %, respectively.
Treatment-induced hypertension rates were notable in
RCC (49.0 %) and HCC (36.1 %) patients, similarly to
other TKIs. Regorafenib-induced hypertension was seen
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mal tumors (GIST) and metastatic colorectal cancer
(mCRC), respectively. The risk for all-grade (RR 3.76,
95 % CI 2.35 to 5.99, p < 0.001) and high-grade (RR 8.39,
95 % CI 3.10 to 22.71, p < 0.001) hypertension associated
with regorafenib therapy was increased significantly [73].Cediranib
Cediranib (Recentin®, AZD2171, Astra-Zeneca), a rela-
tively new agent, targets VEGFR 1, 2, and 3, and c-KIT
[74–76].
A meta-analysis of four phase II and phase III trials of
cediranib indicated increased risk of all-grade hyperten-
sion in 42.1 % of cases (RR 2.63, 95 % CI 1.61 to 4.29, p
< 0.001) [23]. No data on high-grade hypertension was
available in this study. Within clinical trials evaluating
cediranib therapy there is respective evidence of
treatment-induced all-grade and high-grade hyperten-
sion in patients with RCC (64–73 and 19–36 %) [77, 78],
GIST (79 and 29 %) [80], soft tissue sarcoma (40 and
10 %) [79], HCC (41 and 21–29 %) [80, 81], small-cell
lung cancer (52 and 12 %) [82], mesothelioma (70 and
22–32 %) [83, 84], and breast cancer (55 and 19 %) [85].
In a phase II trial of patients with ovarian cancer, com-
bined treatment with cediranib and olaparib showed in-
cidence rates of all-grade and high-grade hypertension
of 80 and 41 %, respectively. In those patients only
treated with olaparib, the incidence was zero [86]. We
calculated the relative risks of treatment-induced hyper-
tension according to published results of a phase III trial
comparing cediranib and bevacizumab, both combined
with mFOLFOX6. The relative risks for all-grade and
high-grade hypertension were 1.60 (95 % CI 1.38 to 1.87,
p < 0.0001) and 1.69 (95 % CI 1.08 to 2.64, p = 0.02) re-
spectively [87].Other notable VSP inhibitors
We found reports of treatment-induced hypertension
caused by other TKIs, regarding cabozantinib [88, 89],
nintedanib [90, 91] and ponatinib [92], inhibitors of the
VEGFR pathway.
Among small-molecule TKIs, some agents induce
hypertension regardless of VEGF inhibition. These in-
clude trametinib, a MEK1/MEK2 inhibitor that does
not appear to affect the VEGF pathway [93, 94].
Interestingly, this effect was shown in patients with
NSCLC, similar to TKIs that affect the VEGF path-
way, and is not described in melanoma and pancreatic
cancer [95–97]. Another non-VSP inhibitor TKI
shown to induce hypertension is ibrutinib, a Bruton’s
tyrosine kinase inhibitor, used for treatment of vari-
ous hematologic malignancies [98].Clinical significance of hypertension in subsequent
cardiac morbidity and as a possible biomarker
The inhibition of the VEGFR pathway may lead to fur-
ther cardiovascular complications, as these pathways
have an effect on the maintenance of myocardial homeo-
stasis under various stressors [99–102]. Animal models
show that cardiotoxicity may present itself secondary to
hypertension [103], yet this hypothesis is not supported
in humans [104].
Several studies have described correlations between
treatment-induced hypertension and prognostic parame-
ters such as progression-free survival (PFS), overall sur-
vival (OS), and overall response rate (ORR) [61, 105–111].
These studies propose that the effect may be dose-
dependent and that hypertension might be indicative of
effective VEGF inhibition and a positive antiangiogenic re-
sponse, and as such could be a biomarker of a favorable
outcome from VSP inhibitors treatment. In the recent
analysis of 770 sunitinib-treated metastatic RCC (mRCC)
patients on-treatment hypertension was associated with
longer PFS (HR 0.37, 95 % CI 0.27–0.52, P < 0.001), and
better OS (HR 0.36, 95 %CI 0.27–0.50, P < 0.001) [112].
Similar results were observed in the study of 38 hepatocel-
lular carcinoma patients treated with sorafenib: time to
progression was 153 days in the hypertension vs 50.5 days
in the non-hypertension group (P < 0.017) and median OS
was 1329 days in the hypertension group versus 302 days
in the non-hypertension group (P < 0.004) [113]. In
contrary, according to the retrospective analysis of 337
metastatic soft tissue sarcoma (STS) patients, pazopanib-
induced hypertension did not correlate with outcome in
pazopanib-treated STS patients. Duffaud et al. [114] con-
clude that the occurrence of hypertension cannot serve as
biomarker in this setting. Probably, using hypertension as
biomarker of VSP inhibitor treatment favorable outcomes
depends on disease process and drug.
Management of hypertension
In the review of previously described studies, treatment-
induced hypertension secondary to VSP inhibition was
most commonly low-grade, and easily corrected with
standard antihypertensive medications. Traditional rec-
ommendations regarding lifestyle changes including
physical exercise, weight reduction, dietary change and
sodium restriction, though potentially beneficial, may be
unachievable in the clinical setting of advanced malig-
nancy [115]. Treatment goal of VSP inhibitor induced
hypertension should be diminishing the short-term risk
of stroke, myocardial infarction, heart failure while en-
suring effective anticancer (antiangiogenic) therapy. Re-
cent meta-analyses pointed to relative risk of 2.23 of
fatal adverse events related to VSP inhibitors compared
to controls [116]. In the absence of specific evidence-
based clinical guidelines Cardiovascular Toxicities Panel
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cardiovascular risk assessment before VSP inhibitor
treatment, active monitoring of blood pressure and car-
diac toxicity and aggressive management of blood pres-
sure elevations and early signs and symptoms of cardiac
toxicity to prevent clinically significant complications of
therapy [117]. Blood pressure target for treatment is
<140/90 mm Hg [118, 119]. Targeting the RAAS has
been advocated although whether there is any significant
difference between angiotensin converting enzyme in-
hibitors (ACEi) or angiotensin receptor antagonists
(ARBs) remains inconclusive [120]. A recent study by
McKay et al. showed a favorable outcomes in patient
with RCC receiving either ACEi or ARBs [121]. The use
of these drugs must take into account the possible im-
pact on renal function and subsequent effects on drug
metabolism during concomitant treatment with cyto-
toxic agents, which depend on renal clearance for their
metabolism, such as cisplatin and pemetrexed. More re-
cent reports cast doubt on the ability of ACEis and
ARBs to have suffice effect in high grade hypertension
[122]. Dihydropyridine calcium channel blockers may be
preferable, specifically in elderly patients who suffer
from isolated systolic hypertension [122]. It is also sug-
gested that calcium channel blockers may beneficially
counteract a reduction in NO production secondary to
VSP inhibition, which would be expected to further en-
hance their vasodilatory mode of action [122]. However,
only dihydropyridine calcium channel blockers, such as
amlodipine or nifedipine, should be used, because non-
dihydropyridine calcium channel blockers, such as diltia-
zem or verapamil (inhibitors of cytochrome P450 3A4),
which metabolizes VEGF inhibitors might lead to poten-
tially high levels in plasma. Caution must be applied,
while using diuretic therapy to avoid the risk of electro-
lyte imbalance. Beta-blocker therapy is a valuable option,
especially in the presence of left ventricular dysfunction
or arrhythmia [120]. When treating patients with antihy-
pertensive agents, special attention needs to be paid to
VSP inhibitor drug protocols in which there are “off” pe-
riods, during which there might be symptomatic re-
bound hypotension and risk of stroke.
Conclusions
Treatment induced hypertension secondary to VSP in-
hibition therapy is a common on-target effect that rarely
requires cessation of cancer therapy. Observed rates of
hypertension may be challenging to quantify for individ-
ual drugs in part reflecting changes to treatment
guidelines.
In our opinion, treatment-induced hypertension with
VSP inhibitors will become more prevalent with in-
creased use of these drugs reflecting earlier diagnosis of
tumors and hence longer duration of therapy. We adviseclinicians to be attentive to this eventuality and ensure
that blood pressure is carefully monitored during a pa-
tient’s follow-up.
There are unanswered questions regarding the nature
of the association between the VSP inhibition and the
induction of hypertension, which may further clarify
why some agents are more prone to this effect than
others. Furthermore, it remains unclear why certain ma-
lignancies, such as RCC, are more susceptible to
treatment-induced hypertension than other cancers.
The precise pathophysiology is still not fully under-
stood. Future trials are also needed to determine the op-
timal choice of antihypertensive agents and therapeutic
goals, which will take into account the complexity of the
advanced oncologic patient, as well as more individual
factors that may apply in specific types of cancer or
other comorbidities.
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